C. Hwang

发表

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

R. Koup, J. Mellors, J. Coffin, 2017, The Journal of infectious diseases.

Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone

T. Garimella, R. Bertz, M. Bifano, 2015, Antimicrobial Agents and Chemotherapy.

Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development

D. Hazuda, E. Asante-Appiah, D. Graham, 2020, Journal of acquired immune deficiency syndromes.

Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial

J. Gatell, H. Teppler, F. Raffi, 2019, Antiviral therapy.

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel, P. Cahn, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Once-Daily Doravirine in HIV-1-Infected, Antiretroviral-Naive Adults: An Integrated Efficacy Analysis.

C. Orkin, A. Rodgers, J. Molina, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects

R. Bertz, M. Bifano, A. Marion, 2015, Clinical Drug Investigation.

Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and Tenofovir

R. Bertz, D. Grasela, M. Bifano, 2013, Antiviral therapy.

Rational Design of Doravirine: From Bench to Patients.

D. Hazuda, M. Lai, C. Hwang, 2020, ACS infectious diseases.

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.

Y. Yazdanpanah, J. Molina, G. Hanna, 2021, The lancet. HIV.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

P. Sax, K. Squires, P. Cahn, 2019, The lancet. HIV.

Effect of the Coadministration of Daclatasvir on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate

R. Bertz, D. Grasela, Hao Jiang, 2014, Antiviral therapy.

Changes in weight and BMI with first-line doravirine-based therapy

C. Orkin, J. Rockstroh, M. Thompson, 2020, AIDS (London, England).

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.

D. Langley, M. Krystal, N. Ray, 2014, The Journal of antimicrobial chemotherapy.

Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068

M. Krystal, J. Whitcomb, N. Ray, 2013, Journal of acquired immune deficiency syndromes.

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance

Min Xu, D. Hazuda, E. Asante-Appiah, 2022, Antimicrobial agents and chemotherapy.

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Tria

P. Ravindran, M. Krystal, A. Hüser, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Randomized, placebo‐controlled single‐ascending‐dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS‐986001, in healthy subjects

R. Bertz, Y. Urata, D. Grasela, 2014, Journal of clinical pharmacology.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial

P. Sax, K. Squires, H. Teppler, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

Y. Yazdanpanah, S. Klopfer, J. Molina, 2021, Journal of acquired immune deficiency syndromes.

Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects with Renal Function Impairment

T. Garimella, R. Bertz, T. Marbury, 2015, Antiviral therapy.

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

H. Teppler, Valerie Teal, J. Mallolas, 2019, Journal of acquired immune deficiency syndromes.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, C. Orkin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

P. Sax, K. Squires, P. Cahn, 2018, The lancet. HIV.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone

T. Garimella, R. Bertz, M. Bifano, 2014, Journal of the International AIDS Society.

Resistance Mutations (NRTI) BMS-986001 against Known NRTI Nucleoside Reverse Transcriptase Inhibitor Cross-Resistance Profile of In Vitro

M. Krystal, G. Hanna, Tricia L. Protack, 2014 .

In Vitro Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations

M. Krystal, G. Hanna, Tricia L. Protack, 2013, Antimicrobial Agents and Chemotherapy.

Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects

Y. Yazdanpanah, F. Raffi, R. Bertz, 2013, Journal of acquired immune deficiency syndromes.

Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis.

P. Sax, K. Squires, P. Cahn, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection

M. Yuen, A. Cathcart, E. Gane, 2022, Journal of Hepatology.

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates

Zeyu Lin, M. Krystal, M. Nijhuis, 2017, Journal of acquired immune deficiency syndromes.

Changes in weight and BMI with first-line doravirine-based therapy

C. Orkin, J. Rockstroh, M. Thompson, 2020, AIDS.

794 THE EFFECT OF COADMINISTRATION OF THE PROTON-PUMP INHIBITOR OMEPRAZOLE ON THE PHARMACOKINETICS OF DACLATASVIR IN HEALTHY SUBJECTS

R. Bertz, M. Bifano, C. Hwang, 2013 .

Pharmacokinetic Interactions between BMS-626529, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug BMS-663068, and Ritonavir or Ritonavir-Boosted Atazanavir in Healthy Subjects

R. Bertz, G. Hanna, M. Furlong, 2015, Antimicrobial Agents and Chemotherapy.

Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone

T. Garimella, R. Bertz, M. Bifano, 2015, Antimicrobial Agents and Chemotherapy.

543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults

P. Sax, J. Gatell, K. Squires, 2018, Open Forum Infectious Diseases.

LB2. Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

M. Bickel, P. Cahn, J. Mallolas, 2018, Open Forum Infectious Diseases.

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial

P. Sax, K. Squires, H. Teppler, 2018, Open Forum Infectious Diseases.

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

K. Yee, W. Greaves, C. Hwang, 2019, Antimicrobial Agents and Chemotherapy.

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.

D. Langley, M. Krystal, N. Ray, 2014, The Journal of antimicrobial chemotherapy.